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Abstract
Background: Current markers for prostate cancer, such as PSA lack specificity. Therefore, novel biomarkers are
needed. Unfortunately, the complexity of body fluids often hampers biomarker discovery. An attractive alternative
approach is the isolation of small vesicles, i.e. exosomes, ,100 nm, which contain proteins that are specific to the tissue
from which they are derived and therefore can be considered as treasure chests for disease-specific biomarker
discovery.
Materials and Methods: Exosomes were isolated from 2 immortalized primary prostate epithelial cells (PNT2C2 and RWPE-
1) and 2 PCa cell lines (PC346C and VCaP) by ultracentrifugation. After tryptic digestion, proteomic analyses utilized a
nanoLC coupled with an LTQ-Orbitrap operated in tandem MS (MS/MS) mode. Accurate Mass and Time (AMT) tag approach
was employed for peptide identification and quantitation. Candidate biomarkers were validated by Western blotting and
Immunohistochemistry.
Results: Proteomic characterization resulted in the identification of 248, 233, 169, and 216 proteins by at least 2 peptides in
exosomes from PNT2C2, RWPE-1, PC346C, and VCaP, respectively. Statistical analyses revealed 52 proteins differently
abundant between PCa and control cells, 9 of which were more abundant in PCa. Validation by Western blotting confirmed
a higher abundance of FASN, XPO1 and PDCD6IP (ALIX) in PCa exosomes.
Conclusions: Identification of exosomal proteins using high performance LC-FTMS resulted in the discovery of PDCD6IP,
FASN, XPO1 and ENO1 as new candidate biomarkers for prostate cancer.
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Introduction
Prostate Specific Antigen (PSA) is a clinically useful protein
biomarker for diagnostics and follow-up after treatment for
prostate cancer (PCa). Nevertheless, PSA-based screening was
shown to have a high risk of overdiagnosis and overtreatment
because it lacks specificity [1,2]. In order to differentiate more
accurately between benign prostate diseases and (different forms)
of PCa, prevent unnecessary prostate biopsies, and support the
urologist in recommending optimal treatment, new molecular
biomarkers are urgently needed.
In the past few decades, a tremendous amount of research has
been performed to find new and better biomarkers for PCa, often
using state-of-the-art mass spectrometry technologies, but the
discovery of novel low abundance protein has been generally
hampered by the complexity of serum or urine [3]. Isolation of
exosomes from body fluids represents an attractive approach to
bypass these limitations and enable detection of candidate (low
abundant) biomarkers.
Recent findings in the search for new biomarkers have revealed
that small exosomes (50–150 nm), are present in serum and urine
[4]. By isolating exosomes from body fluids it should be possible
to overcome the dynamic range challenge and facilitate charac-
terization of tissue/cancer-derived proteins that might more
accurately represent cellular conditions. Therefore exosomes
could be useful for determining individual tumor characteristics
[5,6].
In this study, our goal was to determine the presence and
significance of exosomal proteins as novel candidate biomarkers
for PCa by comparing exosomes from non-cancerous prostate cell
lines to exosomes from PCa cell lines.
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Materials and Methods
Cell culture and isolation
Two human immortalized prostate epithelial cell lines
(PNT2C2 [7] and RWPE-1) and two PCa cell lines (PC346C
[8] and VCaP [9]) were cultured in 10 T175 (175 cm2) culture
flasks (Greiner Bio-One, Frickenhausen, Germany) up to 80–
100% confluency. The PNT2C2 and VCaP cell line were cultured
in RPMI 1640 (Lonza, Verviers, Belgium) and supplemented with
5% and 10% FCS, 500 U penicillin and 500 U streptomycin
(Lonza, Verviers, Belgium). The RWPE-1 cell line (ATCC-LGR,
Wesel, Germany) was cultured in Keratinocyte Serum Free
Medium (Invitrogen, CA, USA) and supplemented with 5 ml
Pen-Strep and a commercial kit containing Bovine Pituitary
Extract (BPE, 0.05 mg/ml) and Epidermal Growth Factor (EGF,
5 ng/ml). The PC346C cell line was cultured in Dulbecco’s
modified Eagle’s medium-Ham’s F-12 medium (Lonza), supple-
mented with multiple additives as described by Marques [10].
After reaching 80–100% confluency, the cells were incubated
with 25 ml serum free medium. After 48 h, the supernatant was
collected and subjected to centrifugation steps of 4006g (10 min),
30006g (20 min), and 10,0006g (30 min) to remove cellular
debris. Exosomes were then pelleted at 64,000 g (110 min), and at
100,000 g (Sucrose gradient) for 1 h [11]. At least two separate
exosomes isolations from each of the four cell lines were pooled.
Total amount and concentration of exosomal proteins of the
pooled samples was measured with a BCA-assay (Pierce, Rock-
ford, IL, USA).
Electron Microscopy (EM)
5 mL of exosomes were spotted onto Formvar-coated grids (200
mesh) and fixed in 2% paraformaldehyde. After fixation the
exosomes were negatively stained using 4% uranylacetate. Grids
were examined by a Philips CM100 electron microscope at 80 kV.
Sample preparation for Mass Spectrometry
TFE (2,2,2-Trifluoroethanol) (Sigma-Aldrich) was added to the
samples to a final concentration of 50%. The samples were
sonicated in an ice-water bath (Branson 1510, Danbury, CT) for
2 minutes and then incubated at 60uC for 2 h with constant
shaking (300 rpm). For protein disulfide bridge (S-S) reduction,
DTT (Dithiothreitol) (Sigma-Aldrich) was added at final concen-
tration of 2 mM, followed by sonication for 2 min. The samples
were spun down and incubated at 37uC for 1 h with shaking
(300 rpm). The samples were diluted, 5-fold with 50 mM
ammonium bicarbonate (pH 7.8) prior to adding sequencing
grade modified trypsin (Promega, Madison, WI) for protein
digestion (1:50 w/w trypsin-to-protein). The samples were shaken
(300 rpm) over-night (16 h). Rapid freezing of the samples in
liquid nitrogen quenched the digestion. All samples were
concentrated down in Speed-Vac SC 250 Express (Thermo
Savant, Holbrook, NY).
Mass spectrometry
Proteomic measurements were performed using a nanoLC-MS
at the Environmental Molecular Science Laboratory (EMSL),
Richland, WA, USA. The analytical platform consisted of an on-
line constant pressure (5000 psi) reversed-phase (C18) liquid
chromatography (RPLC) system [150 mm i.d.6360 mm
o.d.665 cm capillary (Polymicro Technologies Inc., Phoenix,
AZ)] coupled to an LTQ-Orbitrap mass spectrometer (Thermo
Fisher Scientific, San Jose, CA) via an electrospray ionization (ESI)
source manufactured in-house [12]. Briefly, full MS were acquired
over m/z range of 400–2000 at resolution of 100,000, followed by
data-dependent LTQ MS/MS for the top six most abundant ions
in each full MS scan, using a collision energy setting of 35% and
dynamic exclusion time of 60 s. An exponential HPLC gradient of
,100 min (from 0–70% B) was used for each analysis, with mobile
phases consisting of 0.1% formic acid in water (A) and 0.1%
formic acid in ACN (B). Each sample was analyzed in triplicate,
with approximately 5 mg of total peptide consumed (i.e., loaded on
the column) in each analysis.
Mass Spectrometry Data Analysis
The resulting MS data was analyzed using the PNNL developed
Accurate Mass and Time (AMT) Tag pipeline [13]. SEQUEST
software [14] was used to search tandem mass spectra against the
UniProt human database (download on April 5 2011). Confidently
identified peptides (Table S1 in file S1) were assembled into an
exosome-specific AMT tag database. For comparative analyses,
LC-MS features were matched against AMT tags for identification
and relative MS-peak intensities were used to derive change in
abundance. AMT tag approach facilitated quantitation of many
more peptides than spectral counting alone. As long as a peptide
was identified in at least one sample/analysis (by tandem MS), it
could be quantified in all datasets where it was detected, even if the
LC-MS feature was not abundant enough to be fragmented in that
particular analysis. VIPER software [15] was used to correlate
AMT tag entries (identified peptides) with LC-MS features relying
on high mass measurement accuracy (MMA,2 ppm) and
normalized elution time accuracy (NET,2.5%). Consequently,
each LC-MS feature matched back to a single peptide (AMT tag)
thereby giving a peak intensity value (or relative abundance) for
that peptide. For redundant peptide identifications in the case of a
single peptide matching multiple proteins (typically protein
isoforms) a representive protein was chosen; therefore, each
reported peptide matches back to a single protein. No peptide
identifications were made on mass alone.
For the 263 identified proteins, the Human Protein Reference
Database (HPRD) and Ingenuity Pathway Analysis (IPA) were
used to determine subcellular location and biological function
[16].
Selection of potential protein biomarkers for prostate cancer
was performed using two independent approaches. First, proteins
were selected that were present in both PCa cell line derived
exosomes and absent in both non-PCa exosomes. With the second
approach, DAnTE software [17] was used to convert peptide peak
intensity values to a log2 scale and assess them at a protein level
using Rrollup (reference peptide based scaling) parameters where
peptides were excluded from scaling if they were not seen in at
least three datasets and no minimum peptide presence was
required. Proteins presented in this manuscript were identified by
at least two peptides. ANOVA pairwise comparisons between each
PCa and control cell line were also performed in DAnTE where
the minimum number of data points per factor level was set at
three, so that in order for a protein to show statistically significant
changes it would have to be identified in all three replicates.
Significant difference was determined as a p-value and q-value
lower than 0.05. DAnTE generates p-values and estimates their q-
values. The q-value of a test measures the proportion of false
positives incurred (called the false discovery rate) when that
particular test is called significant. Only the significantly different
proteins were selected for unsupervised hierarchical clustering.
Cluster and TreeView software was used to log transform, mean
center relative expression values, and subsequently hierarchical
cluster all the proteins based on their expression [18]. To further
select the most promising proteins, a$1.5 log2 fold change cutoff
was applied along with a requirement that each protein showed
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Table 1. Proteins expression differences.
Protein Description (UniProt Accession #) Gene Symbol
PC346C vs
PNT2C2
PC346C vs
RWPE
VCaP vs
PNT2C2 VCaP vs RWPE
Programmed cell death 6-interacting protein(Q8WUM4)* PDCD6IP 1.64 3.28 1.95 3.59
Elongation factor 1-alpha 2(Q05639) EEF1A2 1.92 3.18 1.83
Fatty acid synthase(P49327)* FASN 1.67 4.06 2.52
Ubiquitin-60S ribosomal protein L40(P62987) UBA52 2.44 1.98 3.03
Vacuolar protein sorting-associated protein 28 homolog(Q9UK41) VPS28 2.22 3.14 2.13
Actin-related protein 3B(Q9P1U1) ACTR3B 5.71 5.27
Basal cell adhesion molecule(P50895) BCAM 1.95 1.95
CD9 antigen(P21926)* CD9 4.13 2.58
Polyadenylate-binding protein 1(P11940) PABPC1 2.89 3.24
14-3-3 protein beta/alpha(P31946) YWHAB 24.88 24.11 22.42 21.64
Annexin A2(P07355) ANXA2 27.86 25.10 25.60 22.84
Sodium/potassium-transporting ATPase subunit alpha-1(P05023) ATP1A1 23.23 22.87 23.38 23.01
Sodium/potassium-transporting ATPase subunit beta-1(P05026) ATP1B1 23.68 23.03 23.52 22.87
Sodium/potassium-transporting ATPase subunit beta-3(P54709) ATP1B3 22.79 22.04 22.33 21.58
Basigin(P35613) BSG 22.90 23.56 24.62 25.28
Chloride intracellular channel protein 1(O00299) CLIC1 25.03 22.85 24.34 22.16
Integrin alpha-6(P23229) ITGA6 22.34 24.84 22.21 24.72
Junctional adhesion molecule A(Q9Y624) F11R 21.56 21.58 22.15 22.17
Actin, aortic smooth muscle(P62736) ACTA2 23.61 23.97 21.83
Potassium-transporting ATPase alpha chain 2(P54707) ATP12A 23.67 22.32 22.89
Catenin beta-1(P35222) CTNNB1 25.02 21.73 22.90
Alpha-enolase(P06733)* ENO1 23.63 21.82 22.18
78 kDa glucose-regulated protein(P11021) HSPA5 23.86 23.56 22.08
Importin subunit beta-1(Q14974) KPNB1 25.13 22.02 22.15
Pyruvate kinase isozymes M1/M2(P14618) PKM2 24.02 22.88 22.19
Triosephosphate isomerase(P60174) TPI1 23.67 22.19 21.62
14-3-3 protein epsilon(P62258) YWHAE 23.70 22.73
14-3-3 protein theta(P27348) YWHAQ 23.17 21.85
4F2 cell-surface antigen heavy chain(P08195) SLC3A2 24.01 25.90
ADP-ribosylation factor 1(P84077) ARF1 23.81 23.12
CD151 antigen(P48509) CD151 24.41 23.12
Coxsackievirus and adenovirus receptor(P78310) CXADR 22.70 21.96
EH domain-containing protein 4(Q9H223) EHD4 22.77 22.18
Prostaglandin F2 receptor negative regulator(Q9P2B2) PTGFRN 21.91 22.76
Putative heat shock protein HSP 90-beta 2(Q58FF8) HSP90AB2P 23.60 21.87
Putative heat shock protein HSP 90-beta-3(Q58FF7) HSP90AB3P 24.05 22.35
Hemoglobin subunit beta(P68871) HBB 25.21 25.19
Ras GTPase-activating-like protein IQGAP1(P46940) IQGAP1 25.14 24.40
Keratin, type I cytoskeletal 9(P35527) KRT9 21.54 21.88
Keratin, type II cytoskeletal 2 epidermal(P35908) KRT2 21.64 21.92
Lactadherin(Q08431) MFGE8 22.02 22.19
Protein DJ-1(Q99497) PARK7 21.80 22.37
Phosphoglycerate kinase 1(P00558) PGK1 22.28 22.13
Peroxiredoxin-1(Q06830) PRDX1 22.43 22.14
Ras-related protein Rab-10(P61026) RAB10 23.10 23.11
Ras-related protein Rab-1A(P62820) RAB1A 22.93 22.11
Ras-related C3 botulinum toxin substrate 1(P63000) RAC1 21.63 22.42
Ras-related protein Rap-1A(P62834) RAP1A 23.01 22.95
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significant change in at least two of the four comparisons listed in
Table 1. Table 1 lists the resulting 52 proteins, 9 of which showed
increased (and 43 decreased) abundance in exosomes derived from
the PCa cells.
To further select the most promising proteins from the two
approaches, proteins were scaled based on prostate preferentiality.
Five different human gene expression atlases [19–23] based on
microarray expression data were combined in SRS [24], to
determine protein-corresponding gene expression. Eventually,
prostate preferentiality was determined as 1.5 fold higher
expression in prostate tissue compared to kidney and bladder
tissue using gene expression microarray data [25].
Western blotting
From every exosome sample 5 mg of protein was mixed with
Laemmli sample buffer (1:1), heated at 95uC for two minutes and
loaded onto 10% one-dimensional SDS-PAGE gels. Subsequently,
proteins were transferred onto Protran nitrocellulose membranes
(Whatman’s Hertogenbosch, the Netherlands) and blocked (1 h)
at room temperature with 5% nonfat dry milk in Tris-Buffered
Saline with 0.1% Tween-20. Then, the gels were incubated
overnight at 4uC with antibodies against: PDCD6IP (1:500
dilution, Sigma-Aldrich), FASN (1:500 dilution, Sigma-Aldrich),
XPO1 (1:200 dilution, Santa Cruz Biotechnology, Heidelberg,
Germany), ENO1 (Clone H300, 1:1000 dilution, Santa Cruz
Biotechnology), GAPDH (Clone 7B, 1:500 dilution, Santa Cruz
Biotechnology), CD9 (Clone 209306, 1:500 dilution, R&D
Systems, Abingdon, UK), PSA (Clone A0562, 1:500 dilution,
DakoCytomation, Heverlee, Belgium). Secondary antibodies
(HRP-conjugated Goat anti Mouse/Rabbit, 1:10,000 dilutions,
DakoCytomation) were incubated for 1 h. BM Chemilumines-
cence Blotting Substrate (POD, Roche Applied Science, Almere)
was used to initiate the oxidation by HRP.
Immunohistochemistry (IHC)
IHC expression analysis of candidate biomarkers was performed
on: normal prostate tissue (NAP, n= 2), PCa Gleason score
3+3= 6 (n= 2), and PCa Gleason score 5+4=9 (n= 2). Tissues
slides were mounted on aminoacetylsilane coated glass slides
(Starfrost, Berlin, Germany), deparaffinised in xylene and dehy-
drated in ethanol. Endogenous peroxidase activity was blocked
with 0.3% hydrogen peroxide in PBS for 20 min. Microwave
pretreatment was performed for 15 min in tris(hydroxymethyl)a-
minomethane-EDTA (pH 9.0). After pretreatment, the slides were
incubated with the PDCD6IP (1:400), FASN (1:50), and XPO1
(1:50) antibodies, overnight at 4uC. Subsequently, the EnVision
DAKO kit (DAKO, Glostrup, Denmark) was used for chromo-
genic visualization. After staining the slides were counterstained
with hematoxylin, washed, dehydrated and mounted in malinol
(Chroma-Geselschaft, Ko¨rgen, Germany).
Results
Isolation and characterization
Electron Microscopy (EM) of the purified exosome samples
revealed that vesicles derived from four cell lines are reasonably
homogeneous in size, with an approximate diameter of 70–
200 nm (Figure 1).
LC-MS/MS analyses after tryptic digestion, identified 1494
non-redundant peptides (Table S1 in file S1), corresponding to
496 proteins by at least 1 peptide (Table S2 in file S1). 263 proteins
were identified by at least 2 peptides, and specifically 248, 233,
169, and 216 proteins were identified in the PNT2C2, RWPE-1,
PC346C and VCaP cell lines, respectively (Table S3 in file S1).
Unsupervised hierarchical clustering of these 263 proteins resulted
in a clear distinction between cancer and control cell lines
(Figure 2).
The identified exosomal proteins in the 4 cell lines showed
similar subcellular localization patterns (Figure 3A). When
compared to all proteins included in the IPA database, exosomes
contain, relatively speaking, more cytoplasmic proteins and almost
no extracellular proteins. A majority of proteins detected within
exosomes relate to tumorigenesis, cell death, protein synthesis,
cellular growth and proliferation (Figure 3B).
Selection of potential biomarkers
To select proteins that show significant change in abundance
between the PCa exosomes and non-PCa exosomes we used
ANOVA pairwise comparisons (i.e., p-value and q-value,0.05,
presence in all analyses, $2 peptides) [17]. Table S4–8 in file S1
contain results obtained for the PC346C (PCa) vs. PNT2C2
(control), PC346C (PCa) vs. RWPE-1 (control), VCaP (PCa) vs.
PNT2C2 (control), and VCaP (PCa) vs. RWPE-1 (control). To
further improve confidence, we required that each protein was
determined to be significantly changing in abundance in at least 2
comparisons; this further reduced our list to 52 proteins (Table 1
and Table S9 in file S1).
Our proteomic analysis indicated PDCD6IP, FASN, CD9, and
ENO1 to have significant change in abundance between two
conditions, while XPO1 did not pass our stringent filtering criteria
and was therefore considered unchanged in abundance in the
VCaP vs. RWPE-1 comparison (Table S8 in file S1). Even so, we
chose to validate XPO1 because of its higher abundance in VCaP
exosomes compared to the RWPE-1 control and the availability of
a high quality antibody suitable for Western blotting and
immunohistochemistry.
Exploration of novel candidate biomarkers
For FASN and XPO1, strong signals were observed in whole
cell lysates as compared to the exosomes and there appears to be
relatively higher abundance within the VCaP exosome sample
Table 1. Cont.
Protein Description (UniProt Accession #) Gene Symbol
PC346C vs
PNT2C2
PC346C vs
RWPE
VCaP vs
PNT2C2 VCaP vs RWPE
Adenosylhomocysteinase(P23526) AHCY 21.97 21.68
Tubulin alpha-1A chain(Q71U36) TUBA1A 23.42 21.80
T-complex protein 1 subunit epsilon(P48643) CCT5 22.72 22.85
UDP-glucose 6-dehydrogenase(O60701) UGDH 23.58 23.13
Proteins with significant abundance changes (.1.50 log2 fold) between prostate cancer and immortalized primary prostate epithelial cell lines.
doi:10.1371/journal.pone.0082589.t001
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(Figure 4). The protein PDCD6IP is enriched in exosomes and
shows higher abundance in both PCa-derived exosome samples as
depicted in Figure 4 and Table 1. Based on the MS analyses,
FASN is significantly higher in the PC346C exosomes compared
to both controls and in VCaP exosomes compared to RWPE-1
control. This higher abundance of FASN in PC346C is confirmed
by the Western blot. CD9 is highly enriched in exosomes and
shows relatively high abundance in the PC346C exosomes. XPO1
exhibited higher abundance in the VCaP exosomes compared to
controls. MS data characterized ENO1 to be significantly
decreased in abundance in PC346C compared to both controls
and in VCaP compared to the PNT2C2 control. Western blotting
of ENO1 revealed an additional band (approximately 30 kDa)
within the two PCa-derived exosome samples. As expected, based
on the difference in PSA-secretion and exosome formation, PSA is
predominately present in the two cancer cell samples and absent in
exosomes. Supernatants that were collected after exosomes were
pelleted during ultracentrifugation, did not contain any of the
exosomal proteins, except ENO1 and GAPDH uniquely in VCaP
medium.
Verification of expression in clinical samples
PDCD6IP showed strong luminal and basal epithelial cytoplas-
mic staining in normal adjacent prostate (NAP), with no alteration
in protein expression in PCa tissue with different Gleason scores
(Figure 5). In NAP, FASN is moderately to highly abundant in
epithelial cells. Nevertheless, when Gleason scores increases,
staining becomes stronger. Regarding XPO1, there is a strong
nuclear abundance in NAP and a weak cytoplasmic staining.
Within PCa cells, the cytoplasmic abundance increases with
Figure 1. Electron microscopic (EM) images of purified exosomes derived from the PNT2C2, RWPE-1, PC346C and VCaP cell lines. All
exosome samples contain multiple vesicles with a size in the range of 70–200 nm. The darkness of the vesicles reflects the difference in density of
exosomes between samples.
doi:10.1371/journal.pone.0082589.g001
Figure 2. Unsupervised hierarchical clustering of differentially abundant proteins (n=263 proteins with .2 peptides) based on
their MS-peak intensity values. Each exosome sample was analyzed in triplicate. Results were mean centered and log-transformed. Relative
protein abundance is colored-coded with red corresponding to a relatively high abundance, green r corresponding to a relatively low abundance,
and grey indicating missing abundance values.
doi:10.1371/journal.pone.0082589.g002
Proteomic Profiling of Prostate Cancer Exosomes
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e82589
Gleason scores. Nuclear staining remains equal among all PCa
tissues.
Discussion
Comparison of exosomes derived from cancer cell lines and
immortalized prostate epithelial cells, provides a powerful tool to
overcome the dynamic range challenge and identify novel low
abundant cancer-derived biomarkers. This unique approach
within exosomal protein research, combined with state-of-the-art
LC-MS analyses facilitated identification of novel candidate
biomarkers for PCa. This study describes exosomal protein
expression from multiple PCa cell lines, but also examines
exosome content from multiple immortalized normal prostate
epithelial cells. As compared to previous studies, this enables us to
more reliably identify PCa-specific candidate biomarkers and
common exosomal proteins. Using Western blotting and IHC, we
verify differential expression and show that the candidate markers
are expressed by prostate cancer cells in patient samples.
The total number of unique proteins we identified in this study
(496 by $1 peptide, 263 by $2 peptides), is comparable with
previously published exosome proteomic reports. [26–30]. Assign-
ment of a subcellular localization revealed that a large proportion
of exosomal proteins normally locate in the cytoplasm or nucleus
of cells. After comparing this to a database containing a vast
majority of all proteins (,20,000), we noticed that exosomes have
a relatively comparable abundance of nuclear proteins, higher
abundance of cytoplasmic proteins and a substantially lower
abundance of extracellular proteins. This fits the current theory of
exosome formation [4]. Exosomes display an over-representation
of transmembrane and cytoplasmic proteins, such as CD9 and
PDCD6IP, as shown by Western blots. This finding agrees with
the theory that biogenesis and selection of exosomal content is not
a random procedure, but at least partly the result of a selective
sorting process [4].
Two recent proteomic studies revealed exosomal proteins
related to prostate cancer [30,31]; Sandvig et al. performed LC-
MS analysis on a single prostate (cancer) cell line, were Hosseini-
Figure 3. Subcellular assignment of the proteins identified within the different samples in panel A. Exosomes from all four cell lines
(PNT2C2, RWPE-1, PC346C, VCaP) contained 60% of cytoplasmic proteins and 25% of transmembrane proteins. B. The top seven functions of
exosomal proteins according to Ingenuity Pathway Analysis. Fisher’s exact test was applied to calculate significance (p-value,0.05).
doi:10.1371/journal.pone.0082589.g003
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Beheshti et al. examined five PCa cell lines and one non-malignant
prostate epithelial cell line. They both reported 266 and 220
proteins, which is similar to the number we revealed. Interestingly,
Sandvig et al. reported a different protein subcellular distribution
and correlation with biological processes as compared to our data.
Sandvig et al. proposed CDCP1 and CD151 as candidate markers,
were Hosseini-Beheshti suggested ANXA2, CLSTN1, FLNC,
FOLH1 and GDF15. Hosseini-Beheshti et al. also showed FASN
to be an exosomes-derived candidate biomarker (in agreement
with our results). When we compare their identified proteins (by
.2 peptides) we noticed an overlap of only 9 proteins, respectively
CD9, ANXA1. ACTB, PGK1, RAN, EPCAM, HSPB1,
PDCD6IP and PRDX1 (Figure 6). These proteins have been
Figure 4. Validation of protein expression by Western blotting. All four exosome samples and their corresponding cell lines were used for
validation. Furthermore, supernatant from the pelleted exosomes was used as a control. The selected proteins FASN, XPO1, CD9 and PDCD6IP, were
tested with ENO1 and GAPDH as controls. PSA was tested to confirm it is secreted through alternative secretion pathway and therefore not present
within exosomes. The nearest protein marker (kDa) is indicated for each blot.
doi:10.1371/journal.pone.0082589.g004
Figure 5. XPO1, FASN and PDCD6IP abundance by immuno-
histochemistry on normal adjacent prostate (NAP), low-grade
prostate cancer (Gleason score 3+3 = 6) and high grade
prostate cancer (Gleason score 4+5=9). Representative pictures
of the staining from 2 independent samples per group.
doi:10.1371/journal.pone.0082589.g005
Figure 6. Comparison of proteins identified by Hosseini-
Beheshti et al., Sandvig et al. and this study visualized by a
Venn diagram. The number of proteins identified in each study are a
compilation of the cancer-derived exosomal proteins identified by MS-
MS.
doi:10.1371/journal.pone.0082589.g006
Proteomic Profiling of Prostate Cancer Exosomes
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e82589
published previously in multiple articles and are considered to be
present in almost all exosomes. PDCD6IP has also been identified
by both researchers, but has not been found to be more abundant
in PCa-derived exosomes. A total of 199 proteins have uniquely
been found in our study, including the candidate biomarker
XPO1. The overlap between the studies is rather limited.
Particularly, an overlap of only 42 proteins between our study
and Hosseini-Beheshti et al. is not expected since party the same
cell lines were utilized (VCaP and RWPE-1). This narrow overlap
could be the result of different purification, MS-MS technologies
and data processing pipelines utilized. In addition, if exosomes
contain a large collection of different proteins, overlap between
databases can be limited if only a fraction of all proteins is
identified in each study. A recent report by Principe et al. showed
the first identification of more than 900 proteins in exosomes
derived from human prostate fluid from patients with low grade
PCa and healthy men [32]. When we compared their unique
protein expression (presence of .2 peptides), only 31 proteins
overlap, including multiple annexins (ANXA1-7), peroxiredoxins
(PRDX1-6), PDCD6IP and general transmembrane proteins
(CD9/CD242/CD44). All these proteins are thought to be present
in almost all exosomes. To what extent the limited overlap is due
to actual differences between cell line-derived exosomes and
vesicles from clinical samples, still needs to be established.
We identified PDCD6IP as being enriched in exosomes,
especially in PCa exosomes. PDCD6IP, also known as ALIX, is
a cytoplasmic protein that is known for its role in apoptosis and is
shown to be involved in the pathway of selected sorting by
ESCRT-complexes [33]. PDCD6IP has been used as a general
marker to prove the presence of exosomes [34]. However, no
association was made with a higher abundance in cancer-derived
exosomes. A possible explanation for high PDCD6IP abundance
in PCa-derived exosomes could be that PCa cells have an altered
production of exosomes, where they are unable to regulate the
sorting of exosomal content properly anymore. It is also possible
that cancerous cells attempt to remove the PDCD6IP protein by
exosome secretion to (partially) suppress apoptosis. To comple-
ment this theory, other non-PCa related studies have shown that
overexpression of PDCD6IP correlates with cell death [35]. Using
IHC, we did not find any difference in PDCD6IP abundance
between normal prostate epithelium and PCa tissue.
Both FASN and XPO1 have a higher abundance in PCa
exosomes derived from VCaP cells. FASN catalyzes the formation
of long chain acids from acetyl-CoA, malonyl-CoA and NADPH
and has already been suggested as a marker for PCa [36,37].
Recent studies showed that FASN is primarily expressed in
hormone-sensitive cells, promote cell proliferation and that the
inhibition of FASN effectively and selectively kills cancer cells [36].
However, these studies were all performed in vitro. The VCaP cell
line used herein is hormone-sensitive, which could explain the
higher abundance of FASN in VCaP-derived exosomes. Cancer
cells produce more FASN, likely because it promotes cell
proliferation, which could lead to higher incorporation into the
exosomes. In agreement with previous results [38], we also
observed an increased abundance in PCa as compared to NAP.
XPO1 has been suggested as a prognostic marker for other
types of cancer [39]. XPO1 is a nuclear protein known to be
involved in nuclear-cytoplasmic export of signal-bearing (NES)
proteins, which play a role in relevant tumor signaling pathways,
such as P53, AKT1, HDAC5, the androgen receptor (AR) and the
EGFR [40–42]. Our findings indicate that XPO1 could be a
potential biomarker for PCa. When this protein is validated on
whole section PCa samples with IHC, we observe a strong nuclear
expression and a very weak cytoplasmic expression. Interestingly,
within cancer cells, this protein seems to translocate into the
cytoplasm. With increasing Gleason score, cytoplasmic XPO1
expression becomes more intense. Why this process occurs
remains unclear. In a normal cell, XPO1 has to be transported
from the cytoplasm back in the nucleus in order to function as a
chaperone protein. If this relocation process is inhibited in cancer,
cytoplasmic XPO1 will accumulate and more XPO1 might get
incorporated in exosomes.
As published previously, an additional protein band (approxi-
mately 30 kDa) appears with Western blotting when using an
antibody directed against ENO1 in the PC346C cell line [43].
Here we show that this band is also present in VCaP exosomes
and absent in exosomes from two non-PCa cell lines. The origin of
the additional band could be a non-specific antibody cross-
reaction to another protein, an alternative spliced ENO1, a
translated fragment or a breakdown product from the original
protein. A known protein isoform called MBP-1 (c-myc promoter-
binding protein-1) is produced form the ENO1 gene [44]. MBP-1
is identical in sequence to ENO1 but lacks the first 93 or 96 amino
acids. With a calculated molecular mass of 36 kDa, MBP-1 is
unlikely the estimated 30 kDa additional band. The observation
that this additional band occurs only in both cancerous samples
could indicate that it might have a relation to PCa.
The new markers we identified came from cell line-derived
exosomes. Although exosomal presence and cancer tissue expres-
sion of a selected set of candidate biomarkers was confirmed using
Western blotting and IHC, independent validation of the
candidate markers is still needed on a large collection of samples
such as patient urinary exosomes or tissue samples. This will
elucidate their role as a biomarker for PCa.
In order to test presence of exosomal proteins in large cohorts of
patient samples, one can resort to standard IHC of candidate
markers on tissue microarrays and prostate biopsies. Alternatively,
intact exosomes can be isolated from urine or plasma using
precipitation, filtration or immunocapture protocols after which
the content of exosomes can be measured by ELISAs, specific for
the proteins of interest. ELISAs are currently being developed for
detection of intact prostate-derived exosomes using capture or
detection antibodies directed against known prostate-specific
transmembrane proteins. Such an assay enables one to identify
expression of transmembrane proteins but also estimate the
number of exosomes.
Conclusion
Prostate (cancer) cells secrete exosomes that can be used to
identify novel candidate biomarkers for PCa. Identification of
exosomal proteins by high performance LC-FTMS resulted in the
discovery of PDCD6IP, FASN, XPO1 and ENO1 as new
candidate biomarkers for PCa. In the next phase, all proposed
candidate biomarkers will be evaluated on patient samples (tissue,
serum or urine) to fully elucidate their potential clinical value.
Supporting Information
File S1 Supporting information that contains 9 sup-
porting information files. Table S1 in file S1: Confidently
identified peptides (n = 1494) were assembled into an exosome-
specific AMT tag database. Table S2 in file S1: 1494 non-
redundant peptides corresponds to 496 proteins by at least 1
peptide. Table S3 in file S1: 263 proteins were identified by at
least 2 peptides, and specifically 248, 233, 169, and 216 proteins
were identified in the PNT2C2, RWPE-1, PC346C and VCaP cell
lines, respectively. Table S4 in file S1: ANOVA pairwise
comparisons were applied (i.e., p-value and q-value,0.05,
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presence in all analyses, $2 peptides) to compare protein
expression between PC346C (PCa) and PNT2C2 (control). Table
S5 in file S1: ANOVA pairwise comparisons were applied (i.e.,
p-value and q-value,0.05, presence in all analyses, $2 peptides)
to compare protein expression between PC346C (PCa) and
RWPE-1 (control). Table S6 in file S1: ANOVA pairwise
comparisons were applied (i.e., p-value and q-value,0.05,
presence in all analyses, $2 peptides) to compare protein
expression between VCaP (PCa) and PNT2C2 (control). Table
S7 in file S1: ANOVA pairwise comparisons were applied (i.e.,
p-value and q-value,0.05, presence in all analyses, $2 peptides)
to compare protein expression between PC346C (PCa) and
PNT2C2 (control). Table S8 in file S1: ANOVA pairwise
comparisons were applied (i.e., p-value and q-value,0.05,
presence in all analyses, $2 peptides) to compare protein
expression between VCaP (PCa) and RWPE-1 (control). Table
S9 in file S1: To further improve confidence, we required that
each protein was determined to be significantly changing in
abundance in at least 2 comparisons; this further reduced our list
to 52 proteins.
(XLSX)
Acknowledgments
We would like to acknowledge Prof. Dr. N. Maitland from the University
of York for kindly providing us with the PNT2C2 cell line. Proteomic
analyses were performed using EMSL, a national scientific user facility
sponsored by the Department of Energy’s Office of Biological and
Environmental Research and located at Pacific Northwest National
Laboratory.
Author Contributions
Conceived and designed the experiments: DD TL LPT GJ. Performed the
experiments: DD MAG AMH MSVB RW. Analyzed the data: DD KEBJ
LPT. Contributed reagents/materials/analysis tools: MAG MSVB. Wrote
the paper: DD KEBJ LPT GJ.
References
1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, et al. (1987) Prostate-
specific antigen as a serum marker for adenocarcinoma of the prostate.
N Engl J Med 317: 909–916.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009)
Screening and prostate-cancer mortality in a randomized European study.
N Engl J Med 360: 1320–1328.
3. Anderson NL, Anderson NG (2002) The human plasma proteome: history,
character, and diagnostic prospects. Mol Cell Proteomics 1: 845–867.
4. Duijvesz D, Luider T, Bangma CH, Jenster G (2010) Exosomes as Biomarker
Treasure Chests for Prostate Cancer. Eur Urol.
5. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13–
21.
6. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, et al. (2009) Oncosome
formation in prostate cancer: association with a region of frequent chromosomal
deletion in metastatic disease. Cancer Res 69: 5601–5609.
7. Berthon P, Cussenot O, Hopwood L, Leduc A, Maitland N (1995) Functional
expression of sv40 in normal human prostatic epithelial and fibroblastic cells -
differentiation pattern of nontumorigenic cell-lines. Int J Oncol 6: 333–343.
8. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der
Kwast TH, et al. (1996) Development of seven new human prostate tumor
xenograft models and their histopathological characterization. Am J Pathol 149:
1055–1062.
9. Korenchuk S, Lehr JE, L MC, Lee YG, Whitney S, et al. (2001) VCaP, a cell-
based model system of human prostate cancer. In Vivo 15: 163–168.
10. Marques RB, van Weerden WM, Erkens-Schulze S, de Ridder CM, Bangma
CH, et al. (2006) The human PC346 xenograft and cell line panel: a model
system for prostate cancer progression. Eur Urol 49: 245–257.
11. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, et al. (2004)
Proteomic analysis of exosomes secreted by human mesothelioma cells.
Am J Pathol 164: 1807–1815.
12. Livesay EA, Tang K, Taylor BK, Buschbach MA, Hopkins DF, et al. (2008)
Fully automated four-column capillary LC-MS system for maximizing
throughput in proteomic analyses. Anal Chem 80: 294–302.
13. Zimmer JS, Monroe ME, Qian WJ, Smith RD (2006) Advances in proteomics
data analysis and display using an accurate mass and time tag approach. Mass
Spectrom Rev 25: 450–482.
14. Yates 3rd JR, Eng JK, McCormack AL, Schieltz D (1995) Method to correlate
tandem mass spectra of modified peptides to amino acid sequences in the protein
database. Anal Chem 67: 1426–1436.
15. Monroe ME, Tolic N, Jaitly N, Shaw JL, Adkins JN, et al. (2007) VIPER: an
advanced software package to support high-throughput LC-MS peptide
identification. Bioinformatics 23: 2021–2023.
16. Prasad TS, Kandasamy K, Pandey A (2009) Human Protein Reference
Database and Human Proteinpedia as discovery tools for systems biology.
Methods Mol Biol 577: 67–79.
17. Polpitiya AD, Qian WJ, Jaitly N, Petyuk VA, Adkins JN, et al. (2008) DAnTE: a
statistical tool for quantitative analysis of -omics data. Bioinformatics 24: 1556–
1558.
18. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:
14863–14868.
19. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. (2004) A gene atlas of
the mouse and human protein-encoding transcriptomes. Proc Natl Acad
Sci U S A 101: 6062–6067.
20. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, et al. (2005) An
atlas of human gene expression from massively parallel signature sequencing
(MPSS). Genome Res 15: 1007–1014.
21. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, et al. (2005)
Interpreting expression profiles of cancers by genome-wide survey of breadth of
expression in normal tissues. Genomics 86: 127–141.
22. Son CG, Bilke S, Davis S, Greer BT, Wei JS, et al. (2005) Database of mRNA
gene expression profiles of multiple human organs. Genome Res 15: 443–450.
23. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, et al. (2005)
A DNA microarray survey of gene expression in normal human tissues. Genome
Biol 6: R22.
24. Veldhoven A, de Lange D, Smid M, de Jager V, Kors JA, et al. (2005) Storing,
linking, and mining microarray databases using SRS. BMC Bioinformatics 6:
192.
25. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010)
Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11–22.
26. Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, et al. (2010) Proteomics
analysis of A33 immunoaffinity-purified exosomes released from the human
colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol
Cell Proteomics 9: 197–208.
27. Raj DA, Fiume I, Capasso G, Pocsfalvi G (2012) A multiplex quantitative
proteomics strategy for protein biomarker studies in urinary exosomes. Kidney
Int.
28. Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, et al. (2010) Proteomics
analysis of bladder cancer exosomes. Mol Cell Proteomics 9: 1324–1338.
29. Jimenez CR, Knol JC, Meijer GA, Fijneman RJ (2010) Proteomics of colorectal
cancer: overview of discovery studies and identification of commonly identified
cancer-associated proteins and candidate CRC serum markers. J Proteomics 73:
1873–1895.
30. Hosseini-Beheshti E, Pham S, Adomat H, Li N, Tomlinson Guns ES (2012)
Exosomes as biomarker enriched microvesicles: characterization of exosomal
proteins derived from a panel of prostate cell lines with distinct AR phenotypes.
Mol Cell Proteomics 11: 863–885.
31. Sandvig K, Llorente A (2012) Proteomic analysis of microvesicles released by the
human prostate cancer cell line PC-3. Mol Cell Proteomics 11: M111 012914.
32. Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, et al. (2013) In-depth
proteomic analyses of exosomes isolated from expressed prostatic secretions in
urine. Proteomics 13: 1667–1671.
33. Odorizzi G (2006) The multiple personalities of Alix. J Cell Sci 119: 3025–3032.
34. Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, et al. (2010)
C2C12 myoblasts release micro-vesicles containing mtDNA and proteins
involved in signal transduction. Exp Cell Res 316: 1977–1984.
35. Hemming FJ, Fraboulet S, Blot B, Sadoul R (2004) Early increase of apoptosis-
linked gene-2 interacting protein X in areas of kainate-induced neurodegener-
ation. Neuroscience 123: 887–895.
36. Liu H, Liu JY, Wu X, Zhang JT (2010) Biochemistry, molecular biology, and
pharmacology of fatty acid synthase, an emerging therapeutic target and
diagnosis/prognosis marker. Int J Biochem Mol Biol 1: 69–89.
37. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, et al. (2009) Fatty acid
synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl
Cancer Inst 101: 519–532.
38. Shah US, Dhir R, Gollin SM, Chandran UR, Lewis D, et al. (2006) Fatty acid
synthase gene overexpression and copy number gain in prostate adenocarcino-
ma. Hum Pathol 37: 401–409.
39. Noske A, Weichert W, Niesporek S, Roske A, Buckendahl AC, et al. (2008)
Expression of the nuclear export protein chromosomal region maintenance/
Proteomic Profiling of Prostate Cancer Exosomes
PLOS ONE | www.plosone.org 9 December 2013 | Volume 8 | Issue 12 | e82589
exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:
1733–1743.
40. Stade K, Ford CS, Guthrie C, Weis K (1997) Exportin 1 (Crm1p) is an essential
nuclear export factor. Cell 90: 1041–1050.
41. Gallouzi IE, Steitz JA (2001) Delineation of mRNA export pathways by the use
of cell-permeable peptides. Science 294: 1895–1901.
42. Saporita AJ, Zhang Q , Navai N, Dincer Z, Hahn J, et al. (2003) Identification
and characterization of a ligand-regulated nuclear export signal in androgen
receptor. J Biol Chem 278: 41998–42005.
43. Jansen FH, Krijgsveld J, van Rijswijk A, van den Bemd GJ, van den Berg MS,
et al. (2009) Exosomal secretion of cytoplasmic prostate cancer xenograft-derived
proteins. Mol Cell Proteomics 8: 1192–1205.
44. Subramanian A, Miller DM (2000) Structural analysis of alpha-enolase.
Mapping the functional domains involved in down-regulation of the c-myc
protooncogene. J Biol Chem 275: 5958–5965.
Proteomic Profiling of Prostate Cancer Exosomes
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e82589
